DaVita Inc
DVA
View Detailed Chart
131.790USD
-1.380-1.04%
Market hours （ET）Quotes delayed by 15 min
9.78BMarket Cap
11.70P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.04%
5 Days
-4.41%
1 Month
-1.93%
6 Months
-8.13%
Year to Date
-11.88%
1 Year
-19.42%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Hold
Current Rating
152.915
Target Price
+14.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 67.08.
Undervalued
The company’s latest PE is 12.82, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 73.92M shares, decreasing 8.01% quarter-over-quarter.
Held by Warren Buffett
Star Investor Warren Buffett holds 32.16M shares of this stock.
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
Ticker SymbolDVA
CompanyDaVita Inc
CEOMr. Javier J. Rodriguez
Websitehttps://www.davita.com/
Related Instruments
-0.02%
-2.65%
+0.38%
-0.74%
-0.85%
-1.55%
-0.61%
-1.45%
-0.38%
+0.13%
-1.04%
-0.14%
+1.26%
+1.36%
-1.16%
-0.37%
-1.00%
-0.71%
0.00%
-0.63%
